Isolation,expansion and characterization of bone marrow-derived mesenchymal stromal cells in serum-free conditions |
| |
Authors: | Sanjay Gottipamula K. M. Ashwin Manjunatha S. Muttigi Suresh Kannan Udaykumar Kolkundkar Raviraja N. Seetharam |
| |
Affiliation: | 1. Stempeutics Research Pvt. Ltd, Shirdi Sai Baba Cancer Hospital, Manipal, India 2. Stempeutics Research Pvt. Ltd, Akshay Tech Park, No: 72 & 73, 2nd floor, EPIP Zone, Phase-I Area, Whitefield, Bangalore, India
|
| |
Abstract: | Bone marrow-derived mesenchymal stromal cells (BM-MSCs) heralded a new beginning for regenerative medicine and generated tremendous interest as the most promising source for therapeutic application. Most cell therapies require stringent regulatory compliance and prefer the use of serum-free media (SFM) or xeno-free media (XFM) for the MSC production process, starting from the isolation onwards. Here, we report on serum-free isolation and expansion of MSCs and compare them with cells grown in conventional fetal bovine serum (FBS)-containing media as a control. The isolation, proliferation and morphology analysis demonstrated significant differences between MSCs cultured in various SFM/XFM in addition to their difference with FBS controls. BD Mosaic? Mesenchymal Stem Cell Serum-Free media (BD-SFM) and Mesencult-XF (MSX) supported the isolation, sequential passaging, tri-lineage differentiation potential and acceptable surface marker expression profile of BM-MSCs. Further, MSCs cultured in SFM showed higher immune suppression and hypo-immunogenicity properties, making them an ideal candidate for allogeneic cell therapy. Although cells cultured in control media have a significantly higher proliferation rate, BM-MSCs cultured in BD-SFM or MSX media are the preferred choice to meet regulatory requirements as they do not contain bovine serum. While BM-MSCs cultured in BD-SFM and MSX media adhered to all MSC characteristics, in the case of few parameters, the performance of cells cultured in BD-SFM was superior to that of MSX media. Pre-clinical safety and efficiency studies are required before qualifying SFM or XFM media-derived MSCs for therapeutic applications. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|